Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AMPH, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Hyaluronidase FDA approved Oct 2004 · Amphadase |
Allergic Skin Reaction | Phase 2 · NCT01689363 | Completed |
| Albuterol | Asthma | Phase 3 · NCT00634829 | Terminated |
| Epinephrine HFA-MDI (E004) | Asthma | Phase 3 · NCT01737905 | Completed |
| E004 (Epinephrine Inhalation Aerosol) HFA-MDI | Asthma | Phase 3 · NCT01460511 | Completed |
| albuterol HFA (Armstrong's) | Asthma | Phase 3 · NCT00635505 | Terminated |
| Albuterol Sulfate Inhalation Aerosol | Asthma | Phase 3 · NCT00634517 | Terminated |
| Armstrong Albuterol Sulfate Inhalation Aerosol | Asthma | Phase 3 · NCT00634517 | Terminated |
| E004 (epinephrine inhalation aerosol), 125 mcg | Asthma | Phase 1/2 · NCT01025648 | Terminated |
| Epinephrine Inhalation Aerosol, HFA | Asthma | Phase 1/2 · NCT01188577 | Completed |
| Histamine | Allergic Skin Reaction | Phase 2 · NCT01689363 | Completed |
| Proventil-HFA | Asthma | Phase 2 · NCT01189396 | Completed |
| Albuterol Sulfate | Asthma | Phase 2 · NCT02210806 | Completed |
| A006 | Asthma | Phase 2 · NCT01189396 | Completed |
| Arm T2: Primatene Mist HFA | Asthma | Phase 2 · NCT01255709 | Completed |
| Arm T1: Primatene Mist HFA | Asthma | Phase 2 · NCT01255709 | Completed |
| Arm T Epinephrine Inhalation Aerosol HFA, 125… | Asthma | Phase 1/2 · NCT01737892 | Terminated |
Also used in these trials (approved or third-party drugs, not AMPH's own candidates): Epinephrine Inhalation, Insulin Aspart.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AMPH holds $234.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AMPH files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER, Director · +149,472 options |
Insider | 9,817,731 | 23.02% | 2026-03-15 |
| Dimensional Fund Advisors LP | Institution (13G, 5%+) | 2,305,107 | 5.40% | 2026-06-30 |
| Rong Zhou SENIOR EVP, PRODUCTION CENTER · +100,765 options |
Insider | 174,203 | 0.41% | 2026-09-16 |
| William J Peters CFO, EVP & TREASURER, Director · +196,578 options |
Insider | 167,076 | 0.39% | 2026-11-04 |
| Howard Lee Director · +17,365 options |
Insider | 159,350 | 0.37% | 2026-06-01 |
| Yakob Liawatidewi EVP CORP ADMIN CENTER, Director · +73,126 options |
Insider | 124,351 | 0.29% | 2026-03-15 |
| Floyd F. Petersen Director |
Insider | 71,368 | 0.17% | 2025-12-11 |
| Michael A Zasloff Director · +17,365 options |
Insider | 37,667 | 0.09% | 2026-06-01 |
| Diane G. Gerst Director · +17,365 options |
Insider | 31,899 | 0.07% | 2026-06-01 |
| Richard K Prins Director · +17,365 options |
Insider | 29,625 | 0.07% | 2026-08-11 |
| Gayle Deflin Director · +17,365 options |
Insider | 19,057 | 0.04% | 2026-06-01 |
| David Russell Gaugh Director · +31,352 options |
Insider | 14,447 | 0.03% | 2026-06-01 |
Share count 42,652,154 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMPH and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →